Chemours (CC) Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chemours in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CC, but not buy additional shares or sell existing shares.
View CC analyst ratings or view top-rated stocks.

10 Wall Street research analysts have issued 1-year target prices for Chemours' shares. Their CC share price forecasts range from $25.00 to $53.00. On average, they anticipate the company's share price to reach $38.22 in the next twelve months. This suggests a possible upside of 28.5% from the stock's current price.
View analysts price targets for CC or view top-rated stocks among Wall Street analysts.

Chemours' stock was trading at $30.62 at the beginning of the year. Since then, CC stock has decreased by 2.9% and is now trading at $29.74.
View the best growth stocks for 2023 here.

Chemours saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 4,840,000 shares, a decrease of 10.4% from the August 15th total of 5,400,000 shares. Based on an average trading volume of 1,390,000 shares, the days-to-cover ratio is presently 3.5 days. Approximately 3.3% of the shares of the stock are short sold.
View Chemours' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, October 24th 2023.
View our CC earnings forecast.

The Chemours Company (NYSE:CC) posted its earnings results on Friday, July, 28th. The specialty chemicals company reported $1.10 earnings per share for the quarter, topping analysts' consensus estimates of $1.09 by $0.01. The specialty chemicals company earned $1.64 billion during the quarter, compared to the consensus estimate of $1.75 billion. Chemours had a negative net margin of 1.40% and a positive trailing twelve-month return on equity of 46.14%. During the same period in the previous year, the company posted $1.89 EPS.

Chemours declared a quarterly dividend on Wednesday, July 26th. Shareholders of record on Tuesday, August 15th will be given a dividend of $0.25 per share on Friday, September 15th. This represents a $1.00 dividend on an annualized basis and a yield of 3.36%. The ex-dividend date is Monday, August 14th.
Read our dividend analysis for CC.

ETFs with the largest weight of Chemours (NYSE:CC) stock in their portfolio include First Trust Materials AlphaDEX Fund (FXZ), First Trust Dorsey Wright Momentum & Dividend ETF (DDIV), Invesco Dorsey Wright Basic Materials Momentum ETF (PYZ), First Trust Dorsey Wright Momentum & Value ETF (DVLU), JPMorgan Active Value ETF (JAVA), Fidelity Small-Mid Cap Opportunities ETF (FSMO), iShares U.S. Basic Materials ETF (IYM) and Avantis U.S. Small Cap Value ETF (AVUV).

Chemours (NYSE:CC) pays an annual dividend of $1.00 per share and currently has a dividend yield of 3.32%.
Read our dividend analysis for CC.

Chemours updated its FY 2023 earnings guidance on Friday, July, 28th. The company provided earnings per share guidance of $3.27-$3.60 for the period, compared to the consensus EPS estimate of $4.02. The company issued revenue guidance of -.

106 employees have rated Chemours Chief Executive Officer Mark Vergnano on Glassdoor.com. Mark Vergnano has an approval rating of 85% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemours investors own include AT&T (T), Pfizer (PFE), DuPont de Nemours (DD), NVIDIA (NVDA), Cisco Systems (CSCO), Micron Technology (MU), Intel (INTC), AbbVie (ABBV), CVS Health (CVS) and Energy Transfer (ET).

Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."

Chemours' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (11.52%), Bank of New York Mellon Corp (3.77%), State Street Corp (2.95%), JPMorgan Chase & Co. (2.36%), LSV Asset Management (1.89%) and Dimensional Fund Advisors LP (1.71%). Insiders that own company stock include Alisha Bellezza, Alvenia Scarborough, David C Shelton, Denise Dignam, Edwin C Sparks, Edwin C Sparks, Mark Newman, Mark P Vergnano, Mark P Vergnano, Matthew S Abbott, Matthew S Abbott and Sameer Ralhan.
View institutional ownership trends.

Shares of CC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CC stock can currently be purchased for approximately $29.74.

Chemours (NYSE:CC) has a market capitalization of $4.40 billion and generates $6.79 billion in revenue each year. The specialty chemicals company earns $578 million in net income (profit) each year or ($0.68) on an earnings per share basis.

The company employs 6,600 workers across the globe.

Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19801. The official website for the company is www.chemours.com. The specialty chemicals company can be reached via phone at (302) 773-1000 or via email at investor@chemours.com.